Pharmaco
GenomeX₂

Make Drug Therapy Safe & Efficient
through Implementation of Algorithms
of Personalized Pharmacotherapy

GET PGX₂ REPORT

PGX₂ – is a bioinformatic cloud service for data analysis and interpretation of pharmacogenetic test performed on the basis of SNP's (real-time PCR) or NGS, with additional estimated risks of polypragmasia.

OUR MISSION

Make safe and efficient drug therapy available in every doctor's routine practice.

Empirical selection of pharmacotherapy is associated with a high risk of adverse drug reactions (ADRs) and pharmacoresistance. Drugs fail to treat and cause ADRs due to individual variability in drug response and toxic reactions and based on a genetic polymorphisms profile, that predetermines the metabolic transformation, pharmacodynamics and medicine conjugation. Numerous studies of the influence of all the genes related to the individual response of a particular patient to a particular drug have shown that such problems are faced by every 5 people in the European population (a mutation of the CYP2D6 gene).

do not show the desired therapeutic effect and cause ADRs. Safe and efficient treatment demands preliminary genetic testing to achieve personalization of drug therapy and avoid the consequences of polypragmasia and pharmacoresistance.

PRODUCT

Software that enables to analyse and interpret you DNA test results (on the basis of 154 polymorphisims) and generates a report that includes 52 drug groups with 655 drugs (more than 5000 generics) of 8 nosologies (psychiatry, neurology, cardiology, alergology, gastroenterology, endocrinology, dermatology and infectious diseases), which is by far the largest database of pharmacogenetic biomarkers in the world.

HOW IT WORKS

TECHOLOGY

Q&A

EVIDENCE BASED DATA

The strongest team of multidisciplinary pharmacogenetics, who are the most cited and productive researchers in various areas of pharmacotherapy (narcology, psychiatry, cardiology, neurology, gynecology, etc) in the Russian Federation and the CIS countries, contributes to the creation of a daily updated scientific basis of PGX₂.

The PGX₂ team has over 100 scientific publications in just 2 years of collaboration. The technology allows to integrate machine deep learning with advanced knowledge of the world pharmacogenetics of Level of evidence 1 to the daily practice of physicians.

OUR PUBLICATIONS

CYP3A subfamily activity affects the equilibrium concentration of Phenazepam® in patients with anxiety disorders and comorbid alcohol use disorder (2020)

Effects of plasma concentration of micro-RNA Mir-27b and CYP3A4*22 on equilibrium concentration of alprazolam in patients with anxiety disorders

How do CYP2C19*2 and CYP2C19*17 genetic polymorphisms affect the efficacy and safety of diazepam in patients with alcohol withdrawal

Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol

Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use

Effects of CYP2C19*2 Polymorphisms on the Efficacy and Safety of Phenazepam in Patients With Anxiety Disorder and Comorbid

ALL ARTICLES

MEDIA

18.04.2020

05.03.2020

15.09.2020

NEWS

11.02.2021

The PGX₂ team took part in the Investor Day at the Skolkovo School of Management.

08.02.2021

PGX₂ CEO – winner of the International Medical Forum "Science. Innovations».

01.02.2021

PGX₂ Science Director accepted into the Royal College of Psychiatrists.

31.12.2020

PGX₂ summed up 2020 results.

10.12.2020

PGX₂ Development Director became the winner of the GSEA MedTech Ru 20-21.

ALL NEWS

TEAM

Mikhael Zastrozhin

FOUNDER, СЕО

PhD, more than 120 articles.

Valentin Scryabin

SCIENCE DIRECTOR

psychiatrist, clinical pharmacologist, more than 50 articles.

Alla Panchenko

BUSINESS DEVELOPMENT

PR and GR management, project management, 8 years of practice in the healthcare market of the Russian Federation, CIS and Asia.

JOBS

PGX2 – is a bioinformatic cloud service for data analysis and interpretation of pharmacogenetic test performed on the basis of SNP's (real-time PCR) or NGS, with additional estimated risks of polypragmasia.